Morphology Matters: A Multidimensional Perspective on Cancer Cell Biology

Abstract

Cancer cell morphology reflects the dynamic interplay between genetic, epigenetic, and environmental factors that drive tumor progression. This review explores the morphological evolution of cancer cells as a phenotypic manifestation of underlying molecular dynamics, drawing on recent advances in evolutionary biology, cytoskeletal remodeling, computational pathology, and tumor metabolism. Clonal evolution, both gradual and punctuated, generates morphological diversity that is shaped by selective pressures from the tumor microenvironment and therapeutic interventions. Studies highlights the structural and mechanical properties, such as reduced cellular stiffness and altered actin organization, are linked to metastatic potential and cytoskeletal deregulation. Oncogenic signaling pathways (e.g., PI3K/AKT, Ras/MAPK) and metabolic reprogramming further modulate cell shape and behavior. High-throughput imaging and machine learning have enabled quantification of both static and dynamic morphological traits, correlating them with chromosomal instability and clinical outcomes. Morphological heterogeneity has emerged as a powerful diagnostic and prognostic biomarker, with deep learning-derived metrics providing scalable tools for cancer classification and risk stratification. Collectively, these insights underscore the clinical utility of integrating morphological analysis with molecular profiling, offering new directions for personalized cancer diagnosis and therapy.

Introduction

1. Importance of Morphology in Cancer
Understanding cancer cell morphology is critical for cancer research and treatment development. Morphological changes—such as loss of polarity, nuclear atypia, and deformability—reflect underlying genetic, epigenetic, and mechanical changes during tumor progression.

2. Genetic and Evolutionary Drivers
Cancer evolves via both Darwinian and non-Darwinian mechanisms. Genetic mutations (e.g., in TP53, RAS, MYC) and chromosomal events like chromothripsis drive morphological diversity. The tumor microenvironment (TME) also exerts selective pressures, influencing phenomena like epithelial-mesenchymal transition (EMT).

3. Molecular and Mechanical Regulators
Key signaling pathways—PI3K/AKT/mTOR, Ras/MAPK, and YAP/TAZ—regulate cytoskeletal dynamics and morphology. Cancer cells typically show softened mechanics, cytoskeletal disorganization, and altered nuclear architecture, facilitating motility and invasiveness. Metabolic reprogramming (e.g., the Warburg effect) supports these morphological shifts by meeting biosynthetic demands.

4. Quantification and Analysis
Modern tools (e.g., deep learning, TISMorph, and single-cell transcriptomics) now enable high-throughput and dynamic analysis of morphology. Studies show that morphological heterogeneity correlates with chromosomal instability and predicts poor clinical outcomes.

5. Clinical Implications
Morphology serves as a functional biomarker of tumor aggressiveness and adaptability. Quantitative digital pathology and computational image analysis can standardize diagnosis and guide therapy, including targeting EMT pathways or drug-resistant cell states.

Conclusion

The integrated analysis of cancer cell morphology across genetic, mechanical, metabolic, and ecological contexts reveals that morphological evolution is not a secondary feature of cancer but a central axis of malignant progression. Morphology embodies the cumulative impact of oncogenic signaling, metabolic reprogramming, microenvironmental pressures, and evolutionary selection. It serves as both a mirror and mediator of cancer dynamics, offering valuable insights into tumor behavior, adaptability, and treatment response. The reviewed literature affirms that morphological plasticity is a key phenotypic expression of cancer’s evolutionary trajectory, and thus, should be incorporated as a core dimension in cancer diagnostics, prognostics, and therapy development. Embracing this perspective can catalyze the discovery of novel morphological biomarkers and the development of targeted interventions that go beyond genomic alterations to include the structural and mechanical vulnerabilities of malignant cells.

References

[1] C. R. Boland and A. Goel, “Somatic evolution of cancer cells,” Dec. 2005. doi: 10.1016/j.semcancer.2005.06.001. [2] “How Cancer Arises,” 1996. [3] M. Gerlinger, N. McGranahan, S. M. Dewhurst, R. A. Burrell, I. Tomlinson, and C. Swanton, “Cancer: Evolution within a lifetime,” Annu Rev Genet, vol. 48, pp. 215–236, Nov. 2014, doi: 10.1146/annurev-genet-120213-092314. [4] R. Vendramin, K. Litchfield, and C. Swanton, “Cancer evolution: Darwin and beyond,” EMBO J, vol. 40, no. 18, Sep. 2021, doi: 10.15252/embj.2021108389. [5] S. Suresh, “Biomechanics and biophysics of cancer cells,” Acta Mater, vol. 55, no. 12, pp. 3989–4014, Jul. 2007, doi: 10.1016/j.actamat.2007.04.022 [6] O. Warburg, “On the Origin of Cancer Cells,” 1956. [Online]. Available: http://www.jstor.orgURL:http://www.jstor.org/stable/1750066 [7] T. N. Seyfried and L. C. Huysentruyt, “On the Origin of Cancer Metastasis,” 2013. [8] R. Axelrod, D. E. Axelrod, and K. J. Pienta, “Evolution of cooperation among tumor cells,” 2006. [Online]. Available: www.pnas.orgcgidoi10.1073pnas.0606053103 [9] E. Alizadeh, J. Castle, A. Quirk, C. D. L. Taylor, W. Xu, and A. Prasad, “Cellular morphological features are predictive markers of cancer cell state,” Comput Biol Med, vol. 126, Nov. 2020, doi: 10.1016/j.compbiomed.2020.104044. [10] E. Sikora, G. Mosieniak, and M. A. Sliwinska, “Send Orders for Reprints to reprints@benthamscience.ae Morphological and Functional Characteristic of Senescent Cancer Cells,” 2016. [11] M. Greaves and C. C. Maley, “Clonal evolution in cancer,” Jan. 19, 2012. doi: 10.1038/nature10762. [12] B. Crespi and K. Summers, “Evolutionary biology of cancer,” Oct. 2005. doi: 10.1016/j.tree.2005.07.007. [13] A. Nurmagambetova, V. Mustyatsa, A. Saidova, and I. Vorobjev, “Morphological and cytoskeleton changes in cells after EMT,” Sci Rep, vol. 13, no. 1, Dec. 2023, doi: 10.1038/s41598-023-48279-y. [14] M. Lekka et al., “Cancer cell recognition - Mechanical phenotype,” Micron, vol. 43, no. 12, pp. 1259–1266, Dec. 2012, doi: 10.1016/j.micron.2012.01.019 [15] R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer cell metabolism,” Feb. 2011. doi: 10.1038/nrc2981 [16] W. Bernhard and N. Granboulan, “THE FINE STRUCTURE OF THE CANCER CELL NUCLEUS,” 1963. [17] R. Nafe, K. Franz, W. Schlote, and B. Schneider, “Morphology of Tumor Cell Nuclei Is Significantly Related with Survival Time of Patients with Glioblastomas.” [Online]. Available: http://aacrjournals.org/clincancerres/article-pdf/11/6/2141/1920895/2141-2148.pdf [18] C. Alibert, B. Goud, J.-B. Manneville, and J. -Baptiste, “Are cancer cells really softer than normal cells?”, doi: 10.1111/boc.201600078ï. [19] A. Abercrombie and A. J. Ambrose, “The Surface Properties of Cancer Cells: A Review,” 1962. [20] A. B. Pardee, “Cancer Cells and Normal Cells,” 1976. [21] M. L. Piacentino, E. J. Hutchins, C. J. Andrews, and M. E. Bronner, “Temporal changes in plasma membrane lipid content induce endocytosis to regulate developmental epithelial-to-mesenchymal transition,” Proc Natl Acad Sci U S A, vol. 119, no. 51, Dec. 2022, doi: 10.1073/pnas.2212879119. [22] R. Sali, Y. Jiang, A. Attaranzadeh, B. Holmes, and R. Li, “Morphological diversity of cancer cells predicts prognosis across tumor types,” J Natl Cancer Inst, vol. 116, no. 4, pp. 555–564, Apr. 2024, doi: 10.1093/jnci/djad243. [23] M. R. Hasan, N. Hassan, R. Khan, Y. T. Kim, and S. M. Iqbal, “Classification of cancer cells using computational analysis of dynamic morphology,” Comput Methods Programs Biomed, vol. 156, pp. 105–112, Mar. 2018, doi: 10.1016/j.cmpb.2017.12.003. [24] X. Zhang et al., “Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT,” Mol Cancer, vol. 18, no. 1, Mar. 2019, doi: 10.1186/s12943-019-0959-5.

Copyright

Copyright © 2025 Rose Rani, Archana Tiwari, Dipanjana Ghosh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.